Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
A Randomized, Open-label, Multi-center Phase III Clinical Study to Evaluate the Safety and Efficacy of Toripalimab (JS001) Combined With Bevacizumab Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Listed as NCT04723004, this PHASE3 trial focuses on Advanced Hepatocellular Carcinoma (HCC) and remains ongoing. Sponsored by Shanghai Junshi Bioscience Co., Ltd., it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 2 earlier versions
-
Jul 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Jul 2022 [monthly]
Recruiting PHASE3
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Junshi Bioscience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Bengbu, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Foshan, China , Ganzhou, China , Gaoxiong, China , Guangzhou, China and 24 more locations